Business
Vivoryon Therapeutics N.V. to Attend and Present in Upcoming Conferences
Vivoryon Therapeutics N.V. to Attend and Present in Upcoming Conferences Halle (Saale) / Munich, Germany, January 7, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that the Company’s management will participate in the following medical and investor conferences: 1x1s around J.P. Morgan Healthcare Confe
About this update from Vivoryon Therapeutics N.v.
[{"type":"image","alt":"Vivoryon Therapeutics N.V.","displaySize":"","headline":null,"caption":"Vivoryon Therapeutics N.V.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":96,"url":"https://media.zenfs.com/en/globenewswire.com/b42ca3f3b80b0385983aa04ad4cdc30c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Iv4MFFdTq5UwH.s30pVCjw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzNDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/b42ca3f3b80b0385983aa04ad4cdc30c","width":300,"height":96}},"lazy":false},{"type":"text","content":"Vivoryon Therapeutics N.V. to Attend and Present in Upcoming Conferences","length":72,"tagName":"p"},{"type":"text","content":"Halle (Saale) / Munich, Germany, January 7, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that the Company’s management will participate in the following medical and investor conferences:","length":386,"tagName":"p"},{"type":"text","content":"1x1s around J.P. Morgan Healthcare Conference San Francisco, USADate: January 12-14, 2026To meet the team contact: [email protected]","length":133,"tagName":"p"},{"type":"text","content":"UBS European Healthcare Conference London, UKDate: March 3-4, 2026","length":68,"tagName":"p"},{"type":"text","content":"World Congress of Nephrology (WCN)Yokohama, JapanDate: March 28-31, 2026Link to conference: https://www.theisn.org/wcn/","length":122,"tagName":"p"},{"type":"text","content":"###","length":3,"tagName":"p"},{"type":"text","content":"About Vivoryon Therapeutics N.V.Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines for the treatment of inflammatory and fibrotic disorders of the kidney. Driven by its passion for ground-breaking science and innovation, the Company strives to improve patient outcomes by changing the course of severe diseases through modulating the activity and stability of pathologically relevant proteins. Vivoryon’s most advanced program, varoglutamstat, a proprietary, first-in-class orally available QPCT/L inhibitor, is being evaluated to treat diabetic kidney disease. www.vivoryon.com","length":648,"tagName":"p"},{"type":"text","content":"Vivoryon Forward ...